Inhibitors of protein kinases
AssigneeAbbott Laboratories
InventorsMichael R. Michaelides, Zhiqin Ji
Life of this patent
Estimating the term…
Abstract
Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.
Claims7
A compound having Formula I
- or a therapeutically acceptable salt thereof, wherein
- A1 is C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, OC(O)OR1, NHC(O)OR1, NR1C(O)OR1 or R5;
- B1 and C1 are independently H, C(O)NHR1, C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)NHR1, NHC(O)N(R1)2, NR1C(O)NHR1, NR1C(O)N(R1)2, SO2NHR1, SO2N(R1)2, NHSO2R1, NR1SO2R1, OC(O)OR1, NHC(O)OR1, NR1C(O)OR1 or R5;
- wherein
- R1 is R2, R3 or R4;
- R2 is phenyl which is unfused or fused with benzene, heteroarene or R2A;
- R2A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R4 is heteroaryl which is unfused or fused with benzene, heteroarene or R3A;
- R3A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R4 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R4A;
- R4A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R5 is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R6, OR6, SR6, S(O)R6, SO2R6, NH2, NHR6, N(R6)2, C(O)R6, C(O)NH2, C(O)NHR6, C(O)N(R6)2, NHC(O)R6, NR6C(O)R6, NHSO2R6, NR6SO2R6, NHC(O)OR6, NR6C(O)OR6, SO2NH2, SO2NHR6, SO2N(R6)2, NHC(O)NH2, NHC(O)R6, NHC(O)N(R6)2, NR6C(O)N(R6)2, OH, (O), C(O)OH, CN, CF3, OCF3, CF2CF3, F, Cl, Br or I;
- R6 is R7, R8, R9, or R9A;
- R7 is phenyl which is unfused or fused with benzene, heteroarene or R7A;
- R7A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R8 is heteroaryl which is unfused or fused with benzene, heteroarene or R8A;
- R8A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R9 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R9A;
- R9A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R9A is alkyl, alkenyl, or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected NH2, C(O)NH2, SO2NH2, NHC(O)NH2, OH, (O), C(O)OH, CN, CF3, OCF3, CF2CF3, F, Cl, Br or I;
- wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected R30, OR30, OCH2R30, SR30, S(O)R30, SO2R30, C(O)R30, CO(O)R30, OC(O)R30, OC(O)OR30, NO2, NH2, NHR30, N(R30)2, C(O)NH2, C(O)NHR30, C(O)N(R30)2, NHC(O)R30, NHC(O)NHR30, NHC(O)N(R30)2, NR30C(O)NHR30, NR30C(O)N(R30)2, C(O)NHOH, C(O)NHOR30, C(O)NHSO2R30, C(O)NR30SO2R30, SO2NH2, SO2NHR30, SO2N(R30)2, CF3, CF2CF3, C(O)H, C(O)OH, C(N)NH2, C(N)NHR30, C(N)N(R30)2, CNOH, CNOCH3, OH, (O), N3, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;
- R30 is R31, R32, R33 or R34;
- R31 is phenyl which is unfused or fused with benzene, heteroarene or R31A;
- R31A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R32 is heteroaryl which is unfused or fused with benzene, heteroarene or R32A;
- R32A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R33 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R33A;
- R33A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R34 is alkyl, alkenyl, or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R35, OR35, SR35, S(O)R35, SO2R35, NH2, NHR35, N(R35)2, C(O)R35, C(O)NH2, C(O)NHR35, C(O)N(R35)2, NHC(O)R35, NR35C(O)R35, NHSO2R35, NR35SO2R35, NHC(O)OR35, NR35C(O)OR35, SO2NH2, SO2NHR35, SO2N(R35)2, NHC(O)NH2, NHC(O)NHR35, NHC(O)R35, NHC(O)N(R35)2, NR35C(O)N(R35)2, OH, (O), C(O)OH, CN, CF3, OCF3, CF2CF3, F, Cl, Br or I;
- R35 is R36, R37, R38 or R39;
- R36 is phenyl which is unfused or fused with benzene, heteroarene or R36A;
- R36A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R37 is heteroaryl which is unfused or fused with benzene, heteroarene or R37A;
- R37A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R38 is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R38A;
- R38A is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;
- R39 is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with R40;
- R40 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl;
- wherein the moieties represented by R31, R32, R33R36, R37 and R38 are independently unsubstituted or substituted with one or two or three of independently selected F, Cl, Br, I, OH, (O)OH, NO2, NH2, CF3, OH, R45, OR45, SR45, S(O)R45, SO2R1, C(O)NHR45, C(O)N(R45)2, NHC(O)R45, NR45C(O)R45, NHC(O)NHR45, NHC(O)N(R45)2, NR45C(O)NHR45, NR45C(O)N(R45)2, SO2NHR45, SO2N(R45)2, NHSO2R45, NR1SO2R45OC(O)OR45, NHC(O)OR45 or NR45C(O)OR45;
- R45 is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R1, F, Cl, Br, I, OH, C(O)OH, NO2 or NH2;
- and
- R50 is phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl.
A composition comprising an excipient and a therapeutically effective amount of a compound having Formula I.
A method of treating bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer or thyroid cancer in a mammal, the method comprising administering thereto a therapeutically effective amount of a compound having Formula I.
Dependencies are inferred from the claim text.